Picture of Cann logo

CAN — Cann News Story

0.000.00%
au flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro CapTurnaround

Australia's Cann Group hits highest in 2 months on GSK Consumer deal

** Shares of Cann Group Ltd  CAN.AX  rise as much as 5.4% to
A$0.295, their highest since Feb 2
    ** The medical cannabis manufacturer says it has entered o
an evaluation-and-option agreement with GSK Consumer
Healthcare urn:newsml:reuters.com:*:nFWN2W30UF
    ** Says agreement is for potential commercialisation of co's
Satipharm CBD capsules for over-the-counter distribution in
Australia, and possibly, other markets globally
    ** Adds that during period of exclusivity, GSK Consumer
Healthcare to undertake evaluation of commercial potential and
will review results of co's Phase 3 CBD clinical trial
    ** Stock down 3.5% this year, as of last close
    

 (Reporting by Archishma Iyer)
 ((Archishma.Iyer@thomsonreuters.com;))

Recent news on Cann

See all news